CVS 2010 Annual Report Download - page 9

Download and view the complete annual report

Please find page 9 of the 2010 CVS annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 82

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82

Specialty pharmacy expenditures are expected
to rise to $100 billion annually by 2015.
Only three of the top 10 drugs in the U.S. in 2006 were specialty drugs, which
require complex and expensive therapies. By 2014, it is estimated that they will
comprise eight of the top 10. With more than $11 billion in specialty revenues
annually, CVS Caremark is well-positioned to capture this growth opportunity.
We are a recognized leader in the specialty industry, with over 30 years of
experience. Specialty drugs can be difficult to administer and can cause chal-
lenging side effects, requiring closer communication between pharmacists and
patients. Our network of specialty pharmacies leverages a team of specialized
clinical pharmacists to support these patients. Through our growing Specialty
Guideline Management program, we’re also helping PBM clients reduce
unnecessary treatment and control their specialty spending.
is this
A Variety of Specialty Prescriptions
- or -
Pharmacy’s Fastest-Growing Sector
?
– 5 –